Posted by Michael Wonder on 09 May 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics announce European Commission authorisation of PRX-102 (pegunigalsidase alfa) for the treatment of Fabry disease
5 May 2023 - PEGylated enzyme replacement therapy designed to provide a long half-life.
Chiesi Global Rare Diseases and Protalix BioTherapeutics today announced that the European Commission has granted marketing authorisation to PRX-102 (pegunigalsidase alfa) in the European Union for the treatment of adult patients with Fabry disease.
